GLP-1 receptor agonists were specifically developed to harness GLP-1's potent hypoglycemic effect in the treatment of diabetes (115): the improved glycemic control results in weight loss in T2D patients and consequently, clinical trials are currently assessing their utility as an anti-obesity drug for patients without T2D (116). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.